Cal Closer to Building "Organs from Scratch"
By JOHN BOITNOTT
Updated 6:32 AM PST, Thu, Mar 5, 2009
Related Topics:Carolyn Bertozzi | Zev Gartner | Biology | Genetics | Life Sciences | Science and Technology | Sciences
Scientists say they expect that eventually, clusters of cells could be built on clusters to make artificial organs that someday may be implanted into humans.
Synthetic biologists are getting closer to creating man-made organs made out of genetically engineered cells.
Two Cal chemists announced Tuesday they have assembled different types of genetically engineered cells into synthetic microtissues that can perform functions such as secreting and responding to hormones.
They said that means more complex biological capabilities, like the kinds done by a liver or a heart or a kidney, are not out of the question at some point soon.
"While the synthetic tissues today comprise only a handful of cells, they could eventually be scaled up to make artificial organs," the university media office said in a statement. "Those could help scientists understand the interactions among cells in the body and might some day substitute for human organs."
"People used to think of the cell as the fundamental unit. But the truth is that there are collections of cells that can do things that no individual cell could ever be programmed to do. We are trying to achieve the properties of organs now, though not yet organisms," "This is like another level of hierarchical complexity for synthetic biology," said coauthor Carolyn Bertozzi, UC Berkeley professor of chemistry and of molecular and cell biology. She is also the director of the Molecular Foundry at Lawrence Berkeley National Laboratory.
"As synthetic biologists cram more and more genes into microbes to make genetically engineered organisms produce ever more complex drugs and chemicals, two University of California chemists have gone a step further," the university media office said.
"We are really taking this into the third dimension now, which for me is particularly exciting," said first author Zev J. Gartner, a former UC Berkeley post-doctoral fellow. "We are not simply linking cells together, we are linking them together in 3-D arrangements, which introduces a whole new level of cellular behavior which you would never see in 2-D environments."
The Hope: Build Organs "From Scratch"
Gartner and Bertozzi report on their assembly of three-dimensional microtissues this week in the online early edition of the journal Proceedings of the National Academy of Sciences.
One type of cell that needs other cells to make it work properly is the stem cell, Bertozzi said
Theoretically, using Gartner and Bertozzi's chemical technique, it should be possible to assemble stem cells with their helper cells into a functioning tissue that would make stem cells easier to study outside the body.
"In principal, we might be able to build a stem cell niche from scratch using our techniques, and then study those very well defined structures in controlled environments," Bertozzi said.
Bertozzi said that most of the body's organs are a collection of many cell types that need to be in actual physical contact to operate properly.
The pancreas, for example, is a collection of specialized cells, including insulin-secreting beta cells, that "sense glucose from the environment and respond by producing insulin. A complex feedback regulatory loop goes into all of this, and you need more than one cell type to achieve such regulation."
"If you really want to understand the way these cells behave in an organism, especially a human, you would like to recapitulate that environment as closely as possible in vitro," Gartner said. "We are trying to do that, with the aim that the rules we learn may help us control them better."
How They Did It…
Gartner and Bertozzi assembled three types of cultured cells into onion-like layers by using two established technologies: DNA hybridization and Staudinger chemistry.
DNA hybridization is like a "programmable glue," she said, that can stick cells together because of the highly precise nature of binding between complementary DNA strands: One strand of the DNA helix binds only to its complementary strand and nothing else. By putting a short DNA strand on the surface of one cell and its complementary strand on another cell, the researchers assure that the two lock together exclusively.
To get these specific DNA strands onto the cells, they used chemical reactions that do not interfere with cellular chemistry but nevertheless stick desired chemicals onto the cell surface.
The technique for adding unusual but benign chemicals to cells was developed by Bertozzi more than a decade ago based on a chemical reaction called the Staudinger ligation.
After proving that they could assemble cells into microtissues, Gartner and Bertozzi constructed a minute gland - analogous to a lymph node, for example - such that one cell type secreted interleukin-3 and thereby kept a second cell type alive.
"What we did is build a little miniaturized, stripped-down system that operates on the same principle and looks like a miniaturized lymph node, an arrangement where two cells communicate with each another and one requires a signal from the other," she said. "The critical thing is that the two cells have to have a cell junction. If you just mix the cells randomly without connection, the system doesn't have the same properties."
She expects that eventually, clusters could be built on clusters to make artificial organs that someday may be implanted into humans.
"Our method allows the assembly of multicellular structures from the bottom up. In other words, we can control the neighbors of each individual cell in a mixed population," she said. "By this method, it may be possible to assemble tissues with more sophisticated properties."
One aspect of the technique is that DNA hybridization seems to be temporary, like a suture. Eventually, the cells may substitute their own cell-cell adhesion molecules for the DNA, creating a well-knit and seemingly normal, biological system.
The research was funded by the U.S. Department of Energy as well as the Howard Hughes Medical Institute.
Find this article at:
http://www.nbcbayarea.com/news/local/Cal-Chemists-Get-Closer-to-Building-Organs-from-Scratch.html
SAVE THIS | EMAIL THIS | Close
Check the box to include the list of links referenced in the article.
© NBC Universal, Inc. | All Rights Reserved.
Thursday, March 5, 2009
Thursday, February 12, 2009
The tale of the teenage toddlers
The tale of the teenage toddlers
By STAFF REPORTERS
Published: 10 Feb 2009
THIS brother and sister might look like cute primary school children but they are actually grown-up TEENAGERS aged 18 and 16.
Shockingly Azad Singh and his sister Laxmi Yadav have not grown at all since they were five or six and still look like little kids.
See incredible pics of the teen tots below:
Neither of the pair, who live in Haryana, India, have been through puberty due to a rare hormone disorder.
Azad is just 3ft tall but is studying for A-Levels in English and Maths with the help of a tutor, and Laxmi, who is 3ft 3ins, is at high school taking the equivalent of her GCSEs.
Mates ... Azad with his school chums
Barcroft Media
The pair face being trapped in children's bodies for their rest of their lives as treatment in the form of hormone injections would normally be given before the age of 16 or 17.
A simple, one-year, course of hormones costing just £18 per day could have allowed them to grow in height and develop sexually.
But the teens parents have always been too poor to fund the injections.
The pair now live in the constant care of mum Manju Bala, dad Bahadur Singh, a casual labourer, and sister Suman Yadav, 12, who is normal height.
Azad, who wants to train as an engineer, said: “I’m taking my exams in April. I’m doing a lot of revision and hard work.
Drive ... tiny Azad takes the wheel
Barcroft Media
“When I go out, such as to walk to my tutor’s house, my mum has to come with me.
“People think I’m still a kid and need looking after.”
He added: “If Laxmi or I go out alone, people stare and gather round us. Some unkind people even shout names at us in the street. So we normally have our parents or sister Suman with us.
“I cannot hang out with boys my age, because they say I cannot keep up with them. But I have two friends at school who spend time with me, and don’t mind that I’m small.”
Laxmi added: “When we were younger our parents had to change our school because the other kids laughed at us because of our size.”
Devoted mum Manju said: “I’m very protective of my children. If I do not accompany Azad when he goes out, people throw things at him on his bike, and might harm him.”
She explained: “When Azad and Laxmi were very young, they were the same size as other children. We didn’t realise anything was wrong until Azad was about five and we noticed he stopped growing.
“When Laxmi also reached five, she’d stopped growing too. We took them to the doctor but he had no idea what was wrong with them.
“Over the years we’ve been referred to many hospitals, but they all wanted payment for any treatment.
“We went to hospitals in Kalavati, Gangaram, but everywhere they were asking for huge money for the treatment. We were not able to afford it, so we had to leave.”
She added: “Once we looked into selling our house to get 15,000 rupees (2,910 pounds) for treatment. But the doctors at Gangaram Hospital could not guarantee us that the injections would work by this stage as Azad and Laxmi were older, so we decided no to go ahead.”
Finally, last year, the family were offered a lifeline by the All India Institute of Medical Sciences in Dehli, who looked into providing free treatment for the brother and sister.
But when the Azad and Laxmi arrived at the hospital, crowds of patients, visitors, and even people from the street went into to the ward to stare at them.
“We could not face all those people,” said Laxmi. “It was too frightening for Azad and me. We felt we would rather stay as we were than go through that.
“We decided we did not want the treatment, as doctors said there was only about a 40 to 50 per cent chance it would work.”
By STAFF REPORTERS
Published: 10 Feb 2009
THIS brother and sister might look like cute primary school children but they are actually grown-up TEENAGERS aged 18 and 16.
Shockingly Azad Singh and his sister Laxmi Yadav have not grown at all since they were five or six and still look like little kids.
See incredible pics of the teen tots below:
Neither of the pair, who live in Haryana, India, have been through puberty due to a rare hormone disorder.
Azad is just 3ft tall but is studying for A-Levels in English and Maths with the help of a tutor, and Laxmi, who is 3ft 3ins, is at high school taking the equivalent of her GCSEs.
Mates ... Azad with his school chums
Barcroft Media
The pair face being trapped in children's bodies for their rest of their lives as treatment in the form of hormone injections would normally be given before the age of 16 or 17.
A simple, one-year, course of hormones costing just £18 per day could have allowed them to grow in height and develop sexually.
But the teens parents have always been too poor to fund the injections.
The pair now live in the constant care of mum Manju Bala, dad Bahadur Singh, a casual labourer, and sister Suman Yadav, 12, who is normal height.
Azad, who wants to train as an engineer, said: “I’m taking my exams in April. I’m doing a lot of revision and hard work.
Drive ... tiny Azad takes the wheel
Barcroft Media
“When I go out, such as to walk to my tutor’s house, my mum has to come with me.
“People think I’m still a kid and need looking after.”
He added: “If Laxmi or I go out alone, people stare and gather round us. Some unkind people even shout names at us in the street. So we normally have our parents or sister Suman with us.
“I cannot hang out with boys my age, because they say I cannot keep up with them. But I have two friends at school who spend time with me, and don’t mind that I’m small.”
Laxmi added: “When we were younger our parents had to change our school because the other kids laughed at us because of our size.”
Devoted mum Manju said: “I’m very protective of my children. If I do not accompany Azad when he goes out, people throw things at him on his bike, and might harm him.”
She explained: “When Azad and Laxmi were very young, they were the same size as other children. We didn’t realise anything was wrong until Azad was about five and we noticed he stopped growing.
“When Laxmi also reached five, she’d stopped growing too. We took them to the doctor but he had no idea what was wrong with them.
“Over the years we’ve been referred to many hospitals, but they all wanted payment for any treatment.
“We went to hospitals in Kalavati, Gangaram, but everywhere they were asking for huge money for the treatment. We were not able to afford it, so we had to leave.”
She added: “Once we looked into selling our house to get 15,000 rupees (2,910 pounds) for treatment. But the doctors at Gangaram Hospital could not guarantee us that the injections would work by this stage as Azad and Laxmi were older, so we decided no to go ahead.”
Finally, last year, the family were offered a lifeline by the All India Institute of Medical Sciences in Dehli, who looked into providing free treatment for the brother and sister.
But when the Azad and Laxmi arrived at the hospital, crowds of patients, visitors, and even people from the street went into to the ward to stare at them.
“We could not face all those people,” said Laxmi. “It was too frightening for Azad and me. We felt we would rather stay as we were than go through that.
“We decided we did not want the treatment, as doctors said there was only about a 40 to 50 per cent chance it would work.”
Stem Cell Heart Trials in UK
Trials for revolutionary stem cell surgery in UK 'within a year'
Heart disease patients in Britain could soon take part in a revolutionary stem cell surgery trial that could change the nature of heart surgery andHeart disease patients in Britain could soon take part in a revolutionary stem cell surgery trial that could change the nature of heart surgery and ultimately end the need for transplants.
By Caroline Gammell
Last Updated: 4:31PM GMT 09 Feb 2009
Heart disease affects more than a million people in the UK and kills around 120,000 people a year Photo: GETTY
It is believed that British patents could take the pioneering treatment, in which a patient's own cells are extracted and grown in a laboratory, in as little as a year.
Scientists have worked out a technique where human bone marrow cells are turned into human heart stem cells and then injected into the heart.
Laboratory grown heart stem cells were initially extensively tested on animals and trials on humans in Europe are due to start later this month.
Dr Jonathan Hill, a consultant cardiologist at London's King's College Hospital, is hoping to perform trials on British patients next year in conjunction with King's College London University.
"I have seen the results of the trials and they are very encouraging," he said. "We are negotiating to carry out human trials in the UK."
Professor Sian Harding, of Imperial College London, said being able to convert bone marrow stem cells into heart stem cell was a "big leap forward" in finding an "effective" treatment for heart failure.
"Placing heart stem cells into the heart to repair has a very good chance of working because the stem cells are the patient's own there are no problems with rejection," she said.
Prof Harding is working on turning embryo stem cells into heart stem cells but said her research was "still years away" from being used in patients.
Dr Duncan Dymond, a consultant cardiologist at London's Bart's Hospital, added: "Turning human stem cells into human heart cells is very exciting news.
"People with bad heart failure often lead a wretched life confined to home and unable to get out and about. If you are lucky you might get a heart transplant but many simply die before their time."
Last month, a method of cloning specialist versions of heart stem cells - known as "progenitor" cells - found in small quantities in human hearts received an international innovation award.
Last year, the Daily Telegraph disclosed how two heart attack patients in Britain had stem cells taken from bone marrow injected into their hearts in a bid to repair damaged tissue.
The most recent process was developed at the Mayo Clinic research centre in Minnesota.
As part of the planned human trials, 40 millilitres of bone marrow will be taken from a volunteer's hips.
The bone marrow is then grown in a laboratory into human heart stem cells using a special 'growth factor' protein.
The growth factor delivers a chemical signal to the stem cells to turn them from bone marrow cells into heart cells.
These cells are then infused into the patient's heart via a catheter in the groin and an improvement in a patient's condition is expected within a couple of weeks.
The development was disclosed during a major stem cell conference in New York and has been submitted to a leading medical journal.
Dr Christian Homsy of Cardio3 Biosciences - the company which is developing human heart stem cells - said: "Human heart stem cells repaired damaged areas of mice hearts in our trials. And we are convinced that we can do the same in humans.
"It is a very straightforward procedure and we would expect to see a patient's health to change quite rapidly over a period of several weeks to a couple of months. In the mouse trials it was quite quick but in humans we don't know yet."
Heart disease affects more than a million people in the UK and kills around 120,000 people a year.
Heart disease patients in Britain could soon take part in a revolutionary stem cell surgery trial that could change the nature of heart surgery andHeart disease patients in Britain could soon take part in a revolutionary stem cell surgery trial that could change the nature of heart surgery and ultimately end the need for transplants.
By Caroline Gammell
Last Updated: 4:31PM GMT 09 Feb 2009
Heart disease affects more than a million people in the UK and kills around 120,000 people a year Photo: GETTY
It is believed that British patents could take the pioneering treatment, in which a patient's own cells are extracted and grown in a laboratory, in as little as a year.
Scientists have worked out a technique where human bone marrow cells are turned into human heart stem cells and then injected into the heart.
Laboratory grown heart stem cells were initially extensively tested on animals and trials on humans in Europe are due to start later this month.
Dr Jonathan Hill, a consultant cardiologist at London's King's College Hospital, is hoping to perform trials on British patients next year in conjunction with King's College London University.
"I have seen the results of the trials and they are very encouraging," he said. "We are negotiating to carry out human trials in the UK."
Professor Sian Harding, of Imperial College London, said being able to convert bone marrow stem cells into heart stem cell was a "big leap forward" in finding an "effective" treatment for heart failure.
"Placing heart stem cells into the heart to repair has a very good chance of working because the stem cells are the patient's own there are no problems with rejection," she said.
Prof Harding is working on turning embryo stem cells into heart stem cells but said her research was "still years away" from being used in patients.
Dr Duncan Dymond, a consultant cardiologist at London's Bart's Hospital, added: "Turning human stem cells into human heart cells is very exciting news.
"People with bad heart failure often lead a wretched life confined to home and unable to get out and about. If you are lucky you might get a heart transplant but many simply die before their time."
Last month, a method of cloning specialist versions of heart stem cells - known as "progenitor" cells - found in small quantities in human hearts received an international innovation award.
Last year, the Daily Telegraph disclosed how two heart attack patients in Britain had stem cells taken from bone marrow injected into their hearts in a bid to repair damaged tissue.
The most recent process was developed at the Mayo Clinic research centre in Minnesota.
As part of the planned human trials, 40 millilitres of bone marrow will be taken from a volunteer's hips.
The bone marrow is then grown in a laboratory into human heart stem cells using a special 'growth factor' protein.
The growth factor delivers a chemical signal to the stem cells to turn them from bone marrow cells into heart cells.
These cells are then infused into the patient's heart via a catheter in the groin and an improvement in a patient's condition is expected within a couple of weeks.
The development was disclosed during a major stem cell conference in New York and has been submitted to a leading medical journal.
Dr Christian Homsy of Cardio3 Biosciences - the company which is developing human heart stem cells - said: "Human heart stem cells repaired damaged areas of mice hearts in our trials. And we are convinced that we can do the same in humans.
"It is a very straightforward procedure and we would expect to see a patient's health to change quite rapidly over a period of several weeks to a couple of months. In the mouse trials it was quite quick but in humans we don't know yet."
Heart disease affects more than a million people in the UK and kills around 120,000 people a year.
Tuesday, January 6, 2009
Folic acid 'increases memory'
Folic acid 'increases memory'
By Nic Fleming, Medical Correspondent
Last Updated: 2:18AM GMT 19 Jan 2007
Folic acid supplements can significantly improve the memory and brain power of older people, according to a study to be published today.
Researchers found that men and post-menopausal women aged between 50 and 70 who took daily doses had the mental abilities of those almost five years their junior.
The supplements also helped maintain speed of information processing, reactions involving movement and overall brain power. These abilities decline with age, and their loss has been linked to a higher risk of dementia.
Folate, the natural form of synthetic folic acid, is found in broccoli, Brussels sprouts, peas, chickpeas, yeast extract, brown rice and fruit including oranges and bananas.
The research, published in the Lancet medical journal, was led by Dr Jane Durga, from the University of Wageningen in the Netherlands.
Dr Durga said: "Folic acid improves performance in tests that measure information processing speed and memory - domains known to decline with age.
"Trials similar to our own should now be repeated to provide greater insight into the clinical relevance of folic acid to people with mild cognitive impairment and dementia."
Folic acid supplements were also found to reduce levels of homocysteine, a blood chemical linked both to heart disease and dementia.
Age Concern has warned that increased consumption could have the side effect of masking deficiencies in the vitamin B12 - found in meat, eggs and dairy products - which could actually cause neurological damage.
"Further research is needed to reach a definitive answer on the benefits, or not, of folic acid," said the charity's director-general Gordon Lishman.
By Nic Fleming, Medical Correspondent
Last Updated: 2:18AM GMT 19 Jan 2007
Folic acid supplements can significantly improve the memory and brain power of older people, according to a study to be published today.
Researchers found that men and post-menopausal women aged between 50 and 70 who took daily doses had the mental abilities of those almost five years their junior.
The supplements also helped maintain speed of information processing, reactions involving movement and overall brain power. These abilities decline with age, and their loss has been linked to a higher risk of dementia.
Folate, the natural form of synthetic folic acid, is found in broccoli, Brussels sprouts, peas, chickpeas, yeast extract, brown rice and fruit including oranges and bananas.
The research, published in the Lancet medical journal, was led by Dr Jane Durga, from the University of Wageningen in the Netherlands.
Dr Durga said: "Folic acid improves performance in tests that measure information processing speed and memory - domains known to decline with age.
"Trials similar to our own should now be repeated to provide greater insight into the clinical relevance of folic acid to people with mild cognitive impairment and dementia."
Folic acid supplements were also found to reduce levels of homocysteine, a blood chemical linked both to heart disease and dementia.
Age Concern has warned that increased consumption could have the side effect of masking deficiencies in the vitamin B12 - found in meat, eggs and dairy products - which could actually cause neurological damage.
"Further research is needed to reach a definitive answer on the benefits, or not, of folic acid," said the charity's director-general Gordon Lishman.
Diabetes dulls the brain claim scientists
1/6/09 12:19 PM
Diabetes dulls the brain claim scientists - Telegraph
http://www.telegraph.co.uk/health/healthnews/4126051/Diabetes-dulls-the-brain-claim-scientists.html
Diabetes dulls the brain claim scientists
People with diabetes suffer a mental slowdown early in the disease, according to a new study.
By Richard Alleyne, Science Correspondent
Last Updated: 3:57PM GMT 05 Jan 2009
Researchers found that healthy adults performed significantly better in planning, paying attention and speed of thought
than those suffering from diabetes.
But the differences were not significant in terms of memory, verbal fluency or reaction time.
As Britain's diabetic population continues to rise sharply, the findings mean that millions of people could be in danger of
mental slow down.
The team from the University of Alberta in Canada tracked 41 people with type 2 diabetes - also known as adult-onset
diabetes - and 424 without to make the finding.
The study, published in the journal Neuropsychology, found that the mental deterioration was no better in younger adults
with diabetes than in an older group, suggesting that the damage is done early in the disease and remains stable
thereafter.
Professor Roger Dixon, the report's co-author, said that people with serious cases of type 2 diabetes should be screened
for these cognitive effects to make sure they get the right medication and advice on diet or mental training.
"There could be some ways to compensate for these declines, at least early and with proper management," he said.
Obesity is one of the principal causes of type 2 diabetes, and has contributed to a rapid rise in the numbers of people with
the condition.
About a quarter of English adults are obese, and one official forecast suggests nine out of ten adults will be overweight or
obese by 2050.
Diabetes is linked to heart disease, stroke, amputations, kidney failure and blindness, and about one in 10 deaths is linked
to the disease. This is forecast to rise to one in eight next year.
Diabetes dulls the brain claim scientists - Telegraph
http://www.telegraph.co.uk/health/healthnews/4126051/Diabetes-dulls-the-brain-claim-scientists.html
Diabetes dulls the brain claim scientists
People with diabetes suffer a mental slowdown early in the disease, according to a new study.
By Richard Alleyne, Science Correspondent
Last Updated: 3:57PM GMT 05 Jan 2009
Researchers found that healthy adults performed significantly better in planning, paying attention and speed of thought
than those suffering from diabetes.
But the differences were not significant in terms of memory, verbal fluency or reaction time.
As Britain's diabetic population continues to rise sharply, the findings mean that millions of people could be in danger of
mental slow down.
The team from the University of Alberta in Canada tracked 41 people with type 2 diabetes - also known as adult-onset
diabetes - and 424 without to make the finding.
The study, published in the journal Neuropsychology, found that the mental deterioration was no better in younger adults
with diabetes than in an older group, suggesting that the damage is done early in the disease and remains stable
thereafter.
Professor Roger Dixon, the report's co-author, said that people with serious cases of type 2 diabetes should be screened
for these cognitive effects to make sure they get the right medication and advice on diet or mental training.
"There could be some ways to compensate for these declines, at least early and with proper management," he said.
Obesity is one of the principal causes of type 2 diabetes, and has contributed to a rapid rise in the numbers of people with
the condition.
About a quarter of English adults are obese, and one official forecast suggests nine out of ten adults will be overweight or
obese by 2050.
Diabetes is linked to heart disease, stroke, amputations, kidney failure and blindness, and about one in 10 deaths is linked
to the disease. This is forecast to rise to one in eight next year.
Thursday, December 18, 2008
Bringing Stem Cells to War: Meet the Blood Pharmers
12/18/08 8:42 PM
Loading “Popular Mechanics”
Page 1 of 2
http://www.popularmechanics.com/science/health_medicine/4296060.html?nav=hpPrint&do=print
Bringing Stem Cells to War: Meet the Blood Pharmers
New research from DARPA could open the door to on-demand blood-cell manufacturing on battlefields and in hospitals. All
medics need is a machine that uses a nanofiber that mimics bone marrow to turn a handful of stem cells into gallons of
blood. Who needs blood donations when you have blood pharming?
By Michael Milstein
Published on: December 16, 2008
Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery.
Military medics are all too familiar with this problem in the field, where donated blood may take two or more weeks to
reach soldiers who need it immediately. But medical researchers—also known as blood pharmers—are working on
manufacturing the red stuff on the spot.
With a machine the size of a few refrigerators, the Defense Department's advanced research arm, the Defense Advanced
Research Projects Agency (DARPA) envisions liter upon liter of fresh blood churning out, destined for the veins of injured soldiers. It
doesn't get any fresher than that. And if it works for the military, it should also work for domestic hospitals that are paying
increasingly pricey bills for blood that's in short supply, says DARPA project scientist Jon Mogford, who was awarded nearly $2
million to Cleveland-based Arteriocyte for blood-pharming research.
The company's key ingredient is umbilical-cord stem cells, the Houdini of human cells, that can transform into whatever other cells
the body might need to repair or replace injured ones. Arteriocyte researchers were trying to grow big batches of stem cells when
they realized that the growing conditions they used—such as temperature and levels of oxygen and carbon dioxide —caused the
stem cells to turn into an early stage of red blood cell. At first they were frustrated because they wanted stem cells. Then they
realized that they may have unintentionally found a clever way to produce new blood.
Blood is in extremely short supply, and not only on the battlefield. Americans today do not donate blood as often as they used to and
many are ineligible to donate because of the risk of hepatitis and other diseases tied to ubiquitous tattoos and piercings. The
shortage has driven the cost of blood up and hospitals are having a hard time getting the kind that they need when they need it.
Even when they do, it may be several days old. On battlefields, the blood may be even older: "It often takes seven to 14 days to get
from my arm to a staging center," said Arteriocyte CEO Donald Brown.
The trick isn't producing red blood cells—the company has that figured out—it is producing them in enough volume to do patients
some good. The cells can be finicky: they need just the right environment to grow. For that, Arteriocyte is relying on a technique
developed at Johns Hopkins University that uses nanofibers to mimic the three-dimensional structure of bone marrow, which
12/18/08 8:42 PM
Loading “Popular Mechanics”
Page 2 of 2
http://www.popularmechanics.com/science/health_medicine/4296060.html?nav=hpPrint&do=print
manufactures blood in the body. Parent stem cells readily multiply in the matrix. "You're trying to replicate what goes on in human
bone marrow," Brown says.
The DARPA award gives Arteriocyte three years to scale up to a self-contained system that could turn out 100 units of universal
blood (which could be transfused into people with any blood type) a week for eight weeks. The system can measure no more than
47 cu ft and must stand up to the rigors of frontline military deployment. DARPA then wants to submit the system to the FDA for
approval. In the end, if the system works, soldiers and civilian patients could have all the blood they need available on tap.
Loading “Popular Mechanics”
Page 1 of 2
http://www.popularmechanics.com/science/health_medicine/4296060.html?nav=hpPrint&do=print
Bringing Stem Cells to War: Meet the Blood Pharmers
New research from DARPA could open the door to on-demand blood-cell manufacturing on battlefields and in hospitals. All
medics need is a machine that uses a nanofiber that mimics bone marrow to turn a handful of stem cells into gallons of
blood. Who needs blood donations when you have blood pharming?
By Michael Milstein
Published on: December 16, 2008
Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery.
Military medics are all too familiar with this problem in the field, where donated blood may take two or more weeks to
reach soldiers who need it immediately. But medical researchers—also known as blood pharmers—are working on
manufacturing the red stuff on the spot.
With a machine the size of a few refrigerators, the Defense Department's advanced research arm, the Defense Advanced
Research Projects Agency (DARPA) envisions liter upon liter of fresh blood churning out, destined for the veins of injured soldiers. It
doesn't get any fresher than that. And if it works for the military, it should also work for domestic hospitals that are paying
increasingly pricey bills for blood that's in short supply, says DARPA project scientist Jon Mogford, who was awarded nearly $2
million to Cleveland-based Arteriocyte for blood-pharming research.
The company's key ingredient is umbilical-cord stem cells, the Houdini of human cells, that can transform into whatever other cells
the body might need to repair or replace injured ones. Arteriocyte researchers were trying to grow big batches of stem cells when
they realized that the growing conditions they used—such as temperature and levels of oxygen and carbon dioxide —caused the
stem cells to turn into an early stage of red blood cell. At first they were frustrated because they wanted stem cells. Then they
realized that they may have unintentionally found a clever way to produce new blood.
Blood is in extremely short supply, and not only on the battlefield. Americans today do not donate blood as often as they used to and
many are ineligible to donate because of the risk of hepatitis and other diseases tied to ubiquitous tattoos and piercings. The
shortage has driven the cost of blood up and hospitals are having a hard time getting the kind that they need when they need it.
Even when they do, it may be several days old. On battlefields, the blood may be even older: "It often takes seven to 14 days to get
from my arm to a staging center," said Arteriocyte CEO Donald Brown.
The trick isn't producing red blood cells—the company has that figured out—it is producing them in enough volume to do patients
some good. The cells can be finicky: they need just the right environment to grow. For that, Arteriocyte is relying on a technique
developed at Johns Hopkins University that uses nanofibers to mimic the three-dimensional structure of bone marrow, which
12/18/08 8:42 PM
Loading “Popular Mechanics”
Page 2 of 2
http://www.popularmechanics.com/science/health_medicine/4296060.html?nav=hpPrint&do=print
manufactures blood in the body. Parent stem cells readily multiply in the matrix. "You're trying to replicate what goes on in human
bone marrow," Brown says.
The DARPA award gives Arteriocyte three years to scale up to a self-contained system that could turn out 100 units of universal
blood (which could be transfused into people with any blood type) a week for eight weeks. The system can measure no more than
47 cu ft and must stand up to the rigors of frontline military deployment. DARPA then wants to submit the system to the FDA for
approval. In the end, if the system works, soldiers and civilian patients could have all the blood they need available on tap.
Wednesday, December 17, 2008
ZYVOX INDICATIONS
http://www.zyvox.com/index.asp?hcp=true
ZYVOX INDICATIONS
ZYVOX® (linezolid) is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:
Nosocomial pneumonia caused by Staphylococcus aureus(methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae(including multidrug-resistant strains [MDRSP]). MDRSP refers to isolates resistant to 2 or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole.
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers.
IMPORTANT SAFETY CONSIDERATIONS
ZYVOX formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components.
ZYVOX should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within 2 weeks of taking any such medicinal product.
Unless patients are monitored for potential increases in blood pressure, ZYVOX should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g. pseudoephedrine), vasopressive agents (e.g. epinephrine, norepinephrine), and dopaminergic agents (e.g. dopamine, dobutamine).
Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, ZYVOX should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine, or buspirone.
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving ZYVOX. In cases where the outcome is known, when ZYVOX was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Complete blood counts should be monitored weekly in patients who receive ZYVOX, particularly in those who receive ZYVOX for longer than 2 weeks, those with preexisting myelosuppression, those receiving concomitant drugs that produce bone marrow suppression, or those with a chronic infection who have received previous or concomitant antibiotic therapy. Discontinuation of therapy with ZYVOX should be considered in patients who develop or have worsening myelosuppression.
ZYVOX is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.
In an open-label investigational study in seriously ill patients with intravascular catheter-related infections, an imbalance in mortality was seen in patients treated with ZYVOX compared with vancomycin/dicloxacillin/oxacillin. While causality has not been established, mortality was higher in patients treated with ZYVOX who were infected with Gram-negative organisms alone, with both Gram-positive and Gram-negative organisms, or who had no infection when they entered the study. Patients with Gram-positive infections had no difference in mortality.
ZYVOX has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Lactic acidosis has been reported with the use of ZYVOX. In reported cases, patients experienced repeated episodes of nausea and vomiting. Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving ZYVOX should receive immediate medical evaluation.
Spontaneous reports of serotonin syndrome associated with the coadministration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported. Where administration of ZYVOX and concomitant serotonergic agents is clinically appropriate, patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination. If signs or symptoms occur, physicians should consider discontinuation of either one or both agents.
Peripheral and optic neuropathy have been reported in patients treated with ZYVOX, primarily those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with ZYVOX for less than 28 days.
If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Visual function should be monitored in all patients taking ZYVOX for extended periods (3 months) and in all patients reporting new visual symptoms regardless of length of therapy with ZYVOX. If peripheral or optic neuropathy occurs, the continued use of ZYVOX in these patients should be weighed against the potential risks.
Convulsions have been reported in patients when treated with ZYVOX. In some of these cases, a history of seizures or risk factors for seizures was reported.
The most commonly reported adverse events in adults across clinical trials were nausea, headache, and diarrhea.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Clostridium difficile –associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C difficile . C difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile , and surgical evaluation should be instituted as clinically indicated.
ZYVOX INDICATIONS
ZYVOX® (linezolid) is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:
Nosocomial pneumonia caused by Staphylococcus aureus(methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae(including multidrug-resistant strains [MDRSP]). MDRSP refers to isolates resistant to 2 or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole.
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers.
IMPORTANT SAFETY CONSIDERATIONS
ZYVOX formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components.
ZYVOX should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid) or within 2 weeks of taking any such medicinal product.
Unless patients are monitored for potential increases in blood pressure, ZYVOX should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g. pseudoephedrine), vasopressive agents (e.g. epinephrine, norepinephrine), and dopaminergic agents (e.g. dopamine, dobutamine).
Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, ZYVOX should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine, or buspirone.
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving ZYVOX. In cases where the outcome is known, when ZYVOX was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Complete blood counts should be monitored weekly in patients who receive ZYVOX, particularly in those who receive ZYVOX for longer than 2 weeks, those with preexisting myelosuppression, those receiving concomitant drugs that produce bone marrow suppression, or those with a chronic infection who have received previous or concomitant antibiotic therapy. Discontinuation of therapy with ZYVOX should be considered in patients who develop or have worsening myelosuppression.
ZYVOX is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.
In an open-label investigational study in seriously ill patients with intravascular catheter-related infections, an imbalance in mortality was seen in patients treated with ZYVOX compared with vancomycin/dicloxacillin/oxacillin. While causality has not been established, mortality was higher in patients treated with ZYVOX who were infected with Gram-negative organisms alone, with both Gram-positive and Gram-negative organisms, or who had no infection when they entered the study. Patients with Gram-positive infections had no difference in mortality.
ZYVOX has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected.
Lactic acidosis has been reported with the use of ZYVOX. In reported cases, patients experienced repeated episodes of nausea and vomiting. Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving ZYVOX should receive immediate medical evaluation.
Spontaneous reports of serotonin syndrome associated with the coadministration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported. Where administration of ZYVOX and concomitant serotonergic agents is clinically appropriate, patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia, and incoordination. If signs or symptoms occur, physicians should consider discontinuation of either one or both agents.
Peripheral and optic neuropathy have been reported in patients treated with ZYVOX, primarily those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with ZYVOX for less than 28 days.
If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Visual function should be monitored in all patients taking ZYVOX for extended periods (3 months) and in all patients reporting new visual symptoms regardless of length of therapy with ZYVOX. If peripheral or optic neuropathy occurs, the continued use of ZYVOX in these patients should be weighed against the potential risks.
Convulsions have been reported in patients when treated with ZYVOX. In some of these cases, a history of seizures or risk factors for seizures was reported.
The most commonly reported adverse events in adults across clinical trials were nausea, headache, and diarrhea.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Clostridium difficile –associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C difficile . C difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C difficile , and surgical evaluation should be instituted as clinically indicated.
Subscribe to:
Posts (Atom)